ClinicalTrials.gg
CompletedNCT06086184ASPIREUpdated Nov 18, 2026

Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder

An interventional study of ACT group therapy in Psychotic Disorders, Acceptance and Commitment Therapy and Psychotherapy, Group, sponsored by Vivantes Netzwerk für Gesundheit GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Vivantes Netzwerk für Gesundheit GmbH · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Psychotic Disorders with a site in Germany — 19 open to participants now, 21 under way, 4 of them phase 3. Psychotic Disorders · Germany.

Enrollment
50th of 65
38 · median 85
Started
2023
with 4 others
No phase
33 of 72
13 open now
Registered
58th of 72
by date

Among the 72 studies in Psychotic Disorders with a site in Germany, this one is the 50th largest by enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2023, is one of 33 with no phase, and was the 58th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

19 of the 72 studies in Psychotic Disorders with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Psychotic Disorders with a site in Germany, or all of them as a file.
02

Study summary

The pilot study that will serve as the basis for the larger project - a multicenter randomized controlled single-blinded trial (RCT) will focus on testing the feasibility and efficacy of an inpatient group ACT treatment program and its effects on symptom severity and patient satisfaction in patients with psychosis spectrum disorder. The ACT-specific treatment program for inpatients with psychosis spectrum disorder is designed to enable patients to deal with their disease in an accepting manner over the long term, to promote self-determined and positive attitudes toward treatment and support options, and thus to reduce rehospitalization rates.

Read the detailed description

Inpatient hospitalization is an important time to provide patients with psychosis spectrum disorder with skills to better manage symptoms and improve functioning after discharge. The long-term goal is to reduce the negative consequences of these disorders and to have a lasting positive impact on the course of the disease. Against this background, the aim of a larger-scale future study project is to evaluate a specific ACT-based four-week treatment program providing inpatient group therapy interventions for patients with psychosis spectrum disorder. The ACT-specific treatment program is designed to enable patients to deal with their disease in an accepting manner over the long term, to promote self-determined and positive attitudes toward treatment and support options, and thus to reduce rehospitalization rates. The pilot study will focus on testing the feasibility and efficacy of the inpatient group ACT treatment program and its effects on symptom severity and patient satisfaction in patients with psychosis spectrum disorder. Here, treatment will include a high-frequency four-week inpatient ACT group therapy program with a focus on the core ACT process of mindfulness in addition to standard inpatient treatment. Within the scope of the survey, possible side effects of the intervention will also be recorded and mapped by conducting qualitative individual interviews and documenting serious adverse events.

03

Conditions studied

  • Psychotic Disorders
  • Acceptance and Commitment Therapy
  • Psychotherapy, Group
  • Inpatients

Browse trials for

Keywords

  • Mindfulness
  • Acceptance and Commitment Therapy
  • Psychotherapy, Group
  • Inpatients
  • Psychotic Disorders
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with psychosis spectrum disorder with the following diagnoses according to the , Fifth Edition ("Schizophrenia Spectrum and Other Psychotic Disorders"):
  • Schizophrenia
  • Schizophreniform disorder
  • Schizoaffective disorder
  • Delusional disorder
  • Brief psychotic disorder
  • Psychotic disorder due to another disorder
  • Substance-induced/medication-induced psychotic disorder
  • Depressive episode with psychotic symptoms
  • Manic or bipolar episode with psychotic symptoms

Exclusion criteria

Exclusion Criteria:

  • Patients decline to participate in the treatment program
  • Language or intellectual abilities insufficient for study participation
  • Absence of dementia
  • 30 points or more in the Global Assessment of Functioning (GAF)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    ACT group therapy

    High-frequency inpatient ACT group therapy program for patients with psychosis spectrum disorder.

    Behavioral: ACT group therapy

Interventions

  • BehavioralACT group therapy

    Participation in four sessions of the inpatient "Compass Group" and eight sessions of the inpatient "Here-and-Now Group". This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan.

06

What researchers measure

Primary outcomes

  1. Positive and Negative Syndrome Scale (PANSS)

    The primary endpoint symptom severity is assessed using the German version of the established Positive and Negative Syndrome Scale (PANSS). The PANSS consists of a third-party assessment interview in which 30 symptoms are rated using a seven-point scale ranging from 1 (nonexistent) to 7 (extreme symptom). Symptoms are assigned to three scales: The Positive Scale, the Negative Scale, and the General Psychopathology Scale. The PANSS is widely used and is considered the gold standard for assessing psychopathology in people with psychotic disorders because of its good reliability and validity.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final examinations: After the end of the four-week intervention (week 5) T2 Follow-up examinations: 6 months after the end of the intervention

Secondary outcomes

  1. Global Assessment of Functioning (GAF)

    The general level of functioning is assessed using the German version of the Global Assessment of Functioning (GAF) numerical external assessment scale. The GAF is divided into 10 levels of functioning with 10 points each and ranges from 100 (highest level of functioning) to 1 (lowest level of functioning). Environmental conditions and physical illness are explicitly not to be considered here. Mental, social, and occupational functioning are thought of as being on a hypothetical continuum from mental health to illness.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention

  2. World Health Organization Quality of Life Brief Version (WHOQOL-BREF)

    Quality of life is measured with the German version of the WHOQOL-BREF (World Health Organization Quality of Life Brief Version), an abbreviated version of the WHOQOL-100 (World Health Organization Quality of Life 100). The WHOQOL-BREF, which is a brief self-report instrument, consists of a total of 26 items, which are assigned to the 4 domains of physical health (7 items), psychological health (6 items), social relationships (3 items) and environmental health (8 items). Two other items measure overall quality of life and general health. Each individual item of the WHOQOL-BREF is scored from 1 to 5 on a response scale, which is stipulated as a five-point ordinal scale (low score of 1 to high score of 5). The average score for each domain is calculated, resulting in an average domain score between 4 and 20. This average domain score is multiplied by 4 to transform it into a scaled score, with a higher score indicating a better quality of life.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention

  3. Fragebogen für Akzeptanz und Handeln (FAH-II)

    German version of the Acceptance and Action Questionnaire (AAQ-II). The AAQ-II was developed to measure experience avoidance based on the model of psychological flexibility. It consists of a 7-point Likert scale. Participants rated between 1 (never true) and 7 (always true) how well the statements describe them. The range of scores is between 7 and 49. Higher scores on the scale indicate higher experience avoidance and lower psychological flexibility.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention

  4. Fragebogen zur Messung der Patientenzufriedenheit (ZUF-8)

    Patient satisfaction at the end of the intervention is assessed using the German version of the self-report scale Client Satisfaction Questionnaire CSQ-8, the ZUF-8 (Questionnaire for the Measurement of Patient Satisfaction). The eight items are formulated as questions and each have four response options, for which 1-4 points are assigned. After reversal of polarity, all eight item values are summed up to the scale value ZUF-8 (theoretical scale range from 8 to 32). High scale values indicate a high level of "satisfaction", low scale values indicate a low level of "satisfaction".

    Time frame: T1 Final Examinations: After the end of the four-week intervention (week 5)

  5. Questionnaire about the Process of Recovery (QPR)

    The German version of the self-report scale Questionnaire about the Process of Recovery (QPR), the Personal Recovery Questionnaire, serves as an instrument for assessing personal recovery. The QPR comprises 15 items, each of which is rated on a 4-point scale (0 = do not agree at all, 1 = do not agree , 2 = partly agree, 3 = agree, 4 = fully agree ) and has been validated in German.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention

  6. Comprehensive Inventory of Mindfulness Experiences (CHIME)

    Mindfulness skills are assessed with the German self-report scale Comprehensive Inventory of Mindfulness Experiences (CHIME). CHIME is a questionnaire for self-assessment of different aspects of mindfulness. It comprises 37 items that are assigned to eight subscales. Items are scored on a 5-point Likert scale ranging from 1 (never) to 5 (very often). The higher the the arithmetic mean the better the mindfulness skills.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention

  7. Cognitive Fusion Questionnaire (CFQ-D)

    Cognitive fusion is assessed with the German version of the self-report questionnaire Cognitive Fusion Questionnaire (CFQ). The Cognitive Fusion Questionnaire (CFQ) assesses cognitive fusion, or rigidly following self-generated rules. The CFQ is a 7 item self-report instrument with a range of 7-49. Higher scores are indicative of a higher level of cognitive fusion.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T1 Final Examinations: After the end of the four-week intervention (week 5) T2 Follow-up Examinations: 6 months after the end of the intervention

Other outcomes

  1. Number of group therapy sessions attended and drop out rate

    To provide evidence on the feasibility and acceptability of the intervention, therapy attendance in the ACT-specific group therapy treatment program (reported as number of group therapy sessions attended) and dropouts from study-related treatment (reported as drop out rate in percent) will be recorded.

    Time frame: Therapy attendance during the four-week intervention will be measured at T1 Final Examinations after the end of the four-week intervention (week 5).

  2. Qualitative semi-structured interview analysis according to Mayring

    A focused, semi-structured guided interview will be used to explore research questions related to the desirable and undesirable effects of inpatient ACT-specific group therapy. The key questions are: 1. What have ACT group therapies done for you? 2. Is this effect desired for you? 3. Did you experience any unwanted effects? 4. What did you notice about your symptoms during and after ACT group therapy sessions? The qualitative individual interviews are recorded with a recording device and transcribed by the study staff. The evaluation of the transcribed, semi-structured interviews on the desired and undesirable effects of the intervention is carried out using the qualitative content analysis method according to Mayring. The qualitative content analysis according to Mayring is a structured, qualitative method for the systematic and theory-driven evaluation of text-based data.

    Time frame: T1 Final Examinations: After the end of the four-week intervention (week 5).

  3. WHO Alcohol, Smoking and Substance Involvement Screening Test (WHO ASSIST)

    Since substance use can have an influence on the development of the measured data to be assessed, substance use will also be systematically recorded.

    Time frame: T0 Baseline Examinations: Before the start of the intervention at study enrollment T2 Follow-up Examinations: 6 months after the end of the intervention

  4. ACT Fidelity Measure (ACT-FM)

    The raters use a German translation of the ACT Fidelity Measure (ACT-FM), which is validated in English and can be used in different therapy contexts.

    Time frame: ACT Fidelity Measure will be evaluated during the four-week intervention.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2025, 23 months.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 23 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Feb 2025 → Oct 2025 and completion Feb 2025 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 17, 2023
StartActual
Oct 17, 2023
Primary completionActual
Oct 16, 2025was Feb 2025
CompletionActual
Nov 16, 2025was Feb 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Sites
1 site added, 1 site removed
Show site
  • Vivantes Klinikum Am Urban · Kreuzberg, Germany
Show 1 removed
  • Vivantes Klinikum Am Urban · Berlin-Kreuzberg, Germany
Nov 18, 2026
Start date
Oct 16, 2023→Oct 17, 2023
Nov 18, 2026
Primary completion
Feb 2025→Oct 16, 2025 (actual)
Nov 18, 2026
Study completion
Feb 2025→Nov 16, 2025 (actual)
Nov 18, 2026
Enrollment
32 (estimated)→38 (actual)
Nov 18, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • EditedPatients with psychosis spectrum disorder with the following diagnoses according to the Diagnostic and Statistical Manual Diploma in Social Medicine 5of Mental Disorders, Fifth Edition ("Schizophrenia Spectrum and Other Psychotic Disorders"):
Exclusion criteria
  • AddedAbsence of dementia
  • Added30 points or more in the Global Assessment of Functioning (GAF)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Vivantes Klinikum Am Urban · Kreuzberg, Germany
    Show 1 removed
    • Vivantes Klinikum Am Urban · Berlin-Kreuzberg, Germany
    Start date Oct 16, 2023→Oct 17, 2023
    Primary completion Feb 2025→Oct 16, 2025 (now actual)
    Study completion Feb 2025→Nov 16, 2025 (now actual)
    Enrollment 32 (estimated)→38 (actual)
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with psychosis spectrum disorder with the following diagnoses according to the Diagnostic and Statistical Manual Diploma in Social Medicine 5of Mental Disorders, Fifth Edition ("Schizophrenia Spectrum and Other Psychotic Disorders"):
    Exclusion criteria
    • AddedAbsence of dementia
    • Added30 points or more in the Global Assessment of Functioning (GAF)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06086184
Lead sponsor
Vivantes Netzwerk für Gesundheit GmbH
Responsible party
Prof. Dr. Andreas Bechdolf (Head of Psychiatry Vivantes Klinikum Am Urban and Klinikum im Friedrichshain, Vivantes Netzwerk für Gesundheit GmbH) — Principal investigator
First posted
Oct 17, 2023
Start date
Oct 17, 2023
Primary completion
Oct 16, 2025
Completion
Nov 16, 2025
Last update
Nov 18, 2026

Study contacts

Andreas Bechdolf, Prof. Dr.
study director · Senior consultant department of psychiatry Vivantes Klinikum Am Urban and Klinikum im Friedrichshain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion